Mason Street Advisors LLC Buys 259 Shares of ICU Medical, Inc. (ICUI)
Mason Street Advisors LLC increased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 8.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,471 shares of the medical instruments supplier’s stock after buying an additional 259 shares during the period. Mason Street Advisors LLC’s holdings in ICU Medical were worth $530,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. Janus Capital Management LLC increased its stake in shares of ICU Medical by 276.1% in the fourth quarter. Janus Capital Management LLC now owns 516,469 shares of the medical instruments supplier’s stock worth $76,108,000 after buying an additional 379,132 shares during the last quarter. Norges Bank bought a new stake in shares of ICU Medical during the fourth quarter worth $18,127,000. Wells Fargo & Company MN increased its stake in shares of ICU Medical by 29.3% in the first quarter. Wells Fargo & Company MN now owns 465,840 shares of the medical instruments supplier’s stock worth $71,133,000 after buying an additional 105,570 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in shares of ICU Medical during the fourth quarter worth $9,871,000. Finally, Castleark Management LLC bought a new stake in shares of ICU Medical during the fourth quarter worth $8,112,000. 77.96% of the stock is currently owned by institutional investors.
Shares of ICU Medical, Inc. (ICUI) opened at 168.80 on Friday. ICU Medical, Inc. has a 1-year low of $103.21 and a 1-year high of $175.73. The stock has a market capitalization of $3.34 billion, a PE ratio of 30.00 and a beta of 0.38. The firm has a 50-day moving average price of $162.41 and a 200-day moving average price of $151.02.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings data on Wednesday, May 10th. The medical instruments supplier reported $1.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.45 by $1.23. The business had revenue of $247.74 million during the quarter, compared to analysts’ expectations of $237.12 million. ICU Medical had a return on equity of 9.63% and a net margin of 18.76%. The business’s quarterly revenue was up 175.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. On average, equities research analysts forecast that ICU Medical, Inc. will post $4.14 earnings per share for the current year.
A number of research firms have commented on ICUI. Zacks Investment Research cut ICU Medical from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 3rd. Roth Capital cut ICU Medical from a “buy” rating to a “neutral” rating in a research note on Thursday, May 11th. They noted that the move was a valuation call.
In other news, VP Alison D. Burcar sold 18,290 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $160.72, for a total transaction of $2,939,568.80. Following the completion of the transaction, the vice president now directly owns 3,727 shares of the company’s stock, valued at approximately $599,003.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Joseph R. Saucedo sold 4,500 shares of the company’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $162.51, for a total value of $731,295.00. Following the transaction, the director now directly owns 3,091 shares of the company’s stock, valued at $502,318.41. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,384 shares of company stock valued at $3,766,450. Insiders own 15.90% of the company’s stock.
About ICU Medical
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI).
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.